PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study

MT Newswires Live09:17

PYC Therapeutics (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of polycystic kidney disease, up to and including 4 milligram-per-kilogram in healthy volunteers, were considered to be safe and well tolerated, according to a Friday Australian bourse filing.

The committee governing the single ascending dose clinical trial reviewed the four-week safety data from all four groups of healthy volunteers enrolled in part A of the study.

The study seeks to evaluate the safety/tolerability profile of the drug candidate, with a secondary objective to evaluate the efficacy of the drug candidate in polycystic kidney disease patients.

The firm does not plan to escalate dosing in healthy volunteers further.

Its shares rose 1% in recent trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592113135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 09:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592113135","market":"us","top_or_hot":-1,"title":"PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study","media":"MT Newswires Live","content":"<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of polycystic kidney disease, up to and including 4 milligram-per-kilogram in healthy volunteers, were considered to be safe and well tolerated, according to a Friday Australian bourse filing.</p><p>The committee governing the single ascending dose clinical trial reviewed the four-week safety data from all four groups of healthy volunteers enrolled in part A of the study.</p><p>The study seeks to evaluate the safety/tolerability profile of the drug candidate, with a secondary objective to evaluate the efficacy of the drug candidate in polycystic kidney disease patients.</p><p>The firm does not plan to escalate dosing in healthy volunteers further.</p><p>Its shares rose 1% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-19 09:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of polycystic kidney disease, up to and including 4 milligram-per-kilogram in healthy volunteers, were considered to be safe and well tolerated, according to a Friday Australian bourse filing.</p><p>The committee governing the single ascending dose clinical trial reviewed the four-week safety data from all four groups of healthy volunteers enrolled in part A of the study.</p><p>The study seeks to evaluate the safety/tolerability profile of the drug candidate, with a secondary objective to evaluate the efficacy of the drug candidate in polycystic kidney disease patients.</p><p>The firm does not plan to escalate dosing in healthy volunteers further.</p><p>Its shares rose 1% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592113135","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592113135","pubTimestamp":1766107027,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PYC Therapeutics (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","BK7067":"生物科技","PYC.AU":"PYC THERAPEUTICS LTD","BK4007":"制药"},"translate_title":"PYC Therapeutics表示，安全审查委员会在1a/1b期研究中确认多囊肾病候选药物剂量的安全性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"PYC.AU":1},"content_text":"PYC Therapeutics (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of polycystic kidney disease, up to and including 4 milligram-per-kilogram in healthy volunteers, were considered to be safe and well tolerated, according to a Friday Australian bourse filing.The committee governing the single ascending dose clinical trial reviewed the four-week safety data from all four groups of healthy volunteers enrolled in part A of the study.The study seeks to evaluate the safety/tolerability profile of the drug candidate, with a secondary objective to evaluate the efficacy of the drug candidate in polycystic kidney disease patients.The firm does not plan to escalate dosing in healthy volunteers further.Its shares rose 1% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592113135","isCrawlerRequest":true}